Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

• Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested
• Chronic dosing over a 12-week treatment period
• Will assess weight loss and blood glucose level control
• Efficacy through possible brain absorption delivery enhancement to be assessed

KELOWNA, BC / ACCESSWIRE / March 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces details of an 8-week animal study WEIGHT-A24-1 (the "Study") to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 ("GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination.

The contract for the Study has been awarded to a third-party, Health Canada-licensed Canadian research laboratory. Manufacturing of the compositions for the first 8 of the 12 arms of the Study has already been completed, and those arms will commence as soon as the testing laboratory is able to do so, expected to begin within 45 days.

Detailed information of the 12 Study arms is as noted:

• Group 1: DehydraTECH-CBD (composition "A")
• Group 2: DehydraTECH-CBD (composition "B")
• Group 3: DehydraTECH-CBD (composition "C")
• Group 4: DehydraTECH-CBD (composition "D")
• Group 5: DehydraTECH-GLP-1 (re-formulated Rybelsus "E")
• Group 6: DehydraTECH-GLP-1 (re-formulated Rybelsus "F")
• Group 7: DehydraTECH-GLP-1 (pure semaglutide "G")
• Group 8: DehydraTECH-GLP-1 (pure liraglutide "H")
• Group 9: Combination of one of E, F, or G and one of A, B, C, or D (TBD)
• Group 10: Combination of H and one of A, B, C, or D (TBD)
• Group 11: Vehicle (placebo) arm
• Group 12: Positive control arm

Each arm of the Study will be dosed for an 8-week period following an acclimation period. During the Study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for purposes of detailed pharmacokinetic drug delivery analyses. Body weight and blood glucose readings will be taken prior to Study start and at regular intervals during and at conclusion of the dosing period. Upon completion of the Study, brain tissue will be analysed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous similar animal studies. LC-MS/MS and other techniques will be used to analyse samples. Also, the Study will allow examination of DehydraTECH-processed semaglutide with and without the salcaprozate sodium "SNAC" technology currently found within Rybelsus tablets. We will be collecting and reporting interim results prior to the end of the Study.